Treatment of immune disorders
AssigneeMesoblast International Sarl
InventorsSilviu Itescu, Paul Simmons
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to stem cells which express high levels of Angeopoetin-1 (Ang1) and uses thereof in inhibiting M1-type macrophage production and treating inflammatory disease such as diabetes.
Claims17
1-18. (canceled)
A method of treating an inflammatory disease in a subject, the method comprising administering to the subject a composition comprising genetically unmodified stem cells wherein said genetically unmodified stem cells express vascular endothelial growth factor (VEGF) in an amount less than 0.05 μg/106 cells.
20-23. (canceled)
26-27. (canceled)
29-30. (canceled)
32-35. (canceled)
37-48. (canceled)
51-52. (canceled)
Dependencies are inferred from the claim text.